Pharmaron Beijing Co., Ltd.

SZSC:3759 Stock Report

Market Cap: HK$46.7b

Pharmaron Beijing Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Boliang Lou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage95.1%
CEO tenure8.1yrs
CEO ownershipn/a
Management average tenure8.1yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Boliang Lou's remuneration changed compared to Pharmaron Beijing's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥2mCN¥2m

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥1b

Jan 01 2023n/an/a

CN¥1b

Sep 30 2022n/an/a

CN¥2b

Jun 30 2022n/an/a

CN¥2b

Mar 31 2022n/an/a

CN¥2b

Dec 31 2021CN¥8mCN¥2m

CN¥2b

Sep 30 2021n/an/a

CN¥1b

Jun 30 2021n/an/a

CN¥1b

Mar 31 2021n/an/a

CN¥1b

Dec 31 2020CN¥4mCN¥2m

CN¥1b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥865m

Mar 31 2020n/an/a

CN¥594m

Dec 31 2019CN¥3mCN¥2m

CN¥547m

Sep 30 2019n/an/a

CN¥437m

Jun 30 2019n/an/a

CN¥378m

Mar 31 2019n/an/a

CN¥346m

Dec 31 2018CN¥3mCN¥2m

CN¥333m

Compensation vs Market: Boliang's total compensation ($USD304.81K) is below average for companies of similar size in the Hong Kong market ($USD887.73K).

Compensation vs Earnings: Boliang's compensation has been consistent with company performance over the past year.

CEO

Boliang Lou (61 yo)

8.1yrs

Tenure

CN¥2,208,000

Compensation

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Leadership Team

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEOno dataCN¥2.21mno data
Xiaoqiang Lou
Co-Founder8.1yrsCN¥1.91m5.66%
HK$ 2.6b
Bei Zheng
Executive VP & Executive Director8.1yrsCN¥1.60m2.12%
HK$ 990.0m
Shing Chung Li
CFO & Secretary of the Boardno dataCN¥1.96mno data
Hua Yang
Chief Scientific Officer & Deputy Manager8.1yrsCN¥1.85mno data
Connie Sun
Senior VP & Global Head of Business Development of Small Moleculesno datano datano data
Celina Zhong
Senior Vice President of Human Resourcesno datano datano data
Katherine Lee
Chief Business Officer13.8yrsno datano data
Stephen Lewinton
Senior Vice President of UK Operationsno datano datano data
Jingqi Huang
Senior Vice President of In Vivo Pharmacologyno datano datano data
Mandy Xu
Senior Vice President of DMPK2.9yrsno datano data
Sid Bhoopathy
Senior VP and US Head of Laboratory Services & CGT3yrsno datano data

8.1yrs

Average Tenure

57yo

Average Age

Experienced Management: 3759's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEO8.1yrsCN¥2.21mno data
Xiaoqiang Lou
Co-Founder8.1yrsCN¥1.91m5.66%
HK$ 2.6b
Bei Zheng
Executive VP & Executive Director8.1yrsCN¥1.60m2.12%
HK$ 990.0m
Kexin Yang
Chairman of the Supervisory Committee8.1yrsno datano data
Jiaqing Li
Non Executive Director8.1yrsno datano data
Kwan Hung Tsang
Independent Non Executive Director5yrsCN¥300.00kno data
Lan Zhang
Employee Representative Supervisor8.1yrsno datano data
Lihua Li
Independent Non Executive Director2.2yrsCN¥300.00k0.0042%
HK$ 2.0m
Jian Yu
Independent Non Executive Director4.3yrsCN¥300.00kno data
Shu Feng
Supervisor3.9yrsno datano data
Qilin Zhou
Independent Non-Executive Director2.2yrsCN¥300.00kno data

8.1yrs

Average Tenure

57yo

Average Age

Experienced Board: 3759's board of directors are considered experienced (8.1 years average tenure).